Understanding human genetic factors influencing primaquine safety and efficacy to guide primaquine roll-out in a pre-elimination setting in southern Africa by Awandu, S.S. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/190993
 
 
 
Please be advised that this information was generated on 2018-05-13 and may be subject to
change.
Awandu et al. Malar J  (2018) 17:120  
https://doi.org/10.1186/s12936-018-2271-z
RESEARCH
Understanding human genetic 
factors influencing primaquine safety 
and efficacy to guide primaquine roll-out 
in a pre-elimination setting in southern Africa
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Abstract 
Background: Primaquine (PQ) is recommended as an addition to standard malaria treatments in pre‑elimination 
settings due to its pronounced activity against mature Plasmodium falciparum gametocytes, the parasite stage 
responsible for onward transmission to mosquitoes. However, PQ may trigger haemolysis in glucose‑6‑phosphate 
dehydrogenase (G6PD)‑deficient individuals. Additional human genetic factors, including polymorphisms in the 
human cytochrome P450 2D6 (CYP2D6) complex, may negatively influence the efficacy of PQ. This study assessed 
the prevalence of G6PD deficiency and two important CYP2D6 variants in representative pre‑elimination settings in 
South Africa, to inform malaria elimination strategies.
Methods: Volunteers (n = 248) attending six primary health care facilities in a malaria‑endemic region of South 
Africa were enrolled between October and November 2015. G6PD status was determined phenotypically, using a 
CareStart™ G6PD rapid diagnostic test (RDT), and genotypically for two common African G6PD variants, namely A+ 
(A376G) and A− (G202A, A542T, G680T & T968C) by PCR, restriction fragment length polymorphisms (RFLP) and DNA 
sequencing. CYP2D6*4 and CYP2D6*17 variants were determined with PCR and RFLP.
Results: A prevalence of 13% (33/248) G6PD deficiency was observed in the cohort by G6PD RDT whilst by geno‑
typic assessment, 32% (79/248) were A+ and 3.2% were A−, respectively. Among the male participants, 11% (6/55) 
were G6PD A− hemizygous; among females 1% (2/193) were G6PD A− homozygous and 16% (32/193) G6PD 
A− heterozygous. The strength of agreement between phenotyping and genotyping result was fair (Cohens Kappa 
κ = 0.310). The negative predictive value for the G6PD RDT for detecting hemizygous, homozygous and heterozygous 
individuals was 0.88 (95% CI 0.85–0.91), compared to the more sensitive genotyping. The CYP2D6*4 allele frequencies 
for CYP2D6*4 (inferred poor metabolizer phenotype) and CYP2D6*17 (inferred intermediate metabolizer phenotype) 
were 3.2 and 19.5%, respectively.
Conclusions: Phenotypic and genotypic analyses both detected low prevalence of G6PD deficiency and the 
CYP2D6*4 variants. These findings, combined with increasing data confirming safety of single low‑dose PQ in individ‑
uals with African variants of G6PD deficiency, supports the deployment of single low‑dose PQ as a gametocytocidal 
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Background
South Africa is one of eight southern African countries 
that are signatories of the Elimination 8 (E8) initiative, 
a multi-country coordinated effort to achieve malaria 
elimination. The four frontline countries (South Africa, 
Botswana, Namibia and Swaziland) aim for elimination, 
in various timeframes by 2020 [1], thus setting the stage 
for subsequent elimination in the other E8 member states 
[2]. In an effort to accelerate the region towards malaria 
elimination, novel parasite and integrated vector tools are 
being explored.
For treatment of patients with Plasmodium falcipa-
rum malaria, the World Health Organization (WHO) 
advocates the use of a single low-dose (0.25  mg/kg) of 
primaquine (PQ) together with artemisinin-based com-
bination therapy in malaria-eliminating countries [3]. PQ 
is effective against the transmissible gametocyte stage of 
P. falciparum parasites and may reduce onward transmis-
sion to mosquitoes if deployed at community level [4, 
5]. It is also the only commercially-available drug active 
against hypnozoites in Plasmodium vivax and Plasmo-
dium ovale infections [6]. However, country-specific 
efforts towards low-dose PQ deployment for P. falcipa-
rum transmission reduction are being impeded by the 
perceived safety issue surrounding PQ use in glucose-
6-phosphate dehydrogenase (G6PD)-deficient individu-
als. When exposed to high doses of 8-aminoquinoline 
anti-malarial agents like PQ and tafenoquine, G6PD-
deficient individuals risk suffering haemolysis [6, 7]. 
However, at the recommended low dose, the risk of hae-
molysis is thought to be substantially reduced and PQ is 
considered safe [3].
G6PD deficiency is an X-linked genetic disorder that 
displays great polymorphism with about 186 described 
mutations [8], resulting in the most common enzymo-
pathy in the world [7]. G6PD deficiency is clinically 
observed mainly in hemizygous males or homozygous 
females, with heterozygous females presenting with 
a wide spectrum of aberrant enzyme activities due to 
mosaicism. Circumstantial evidence suggests that G6PD 
deficiency imparts some resistance against malaria as evi-
denced by the overlap in the geographical distribution of 
the deficiency with present and past malaria endemicity 
[9], although the exact nature of such potential protection 
is unknown. Whilst earlier studies reported G6PD defi-
ciency protection against severe forms of malaria [10, 11], 
recent data from a large multi-centre case control study 
and a meta-analysis suggests protection from cerebral 
malaria and high parasitaemia and not severe malarial 
anaemia, mainly in heterozygous individuals in African 
settings [12, 13]. Although the complexity of this disorder 
presents a diagnostic challenge, certain G6PD variants, 
including the African and Mediterranean variants, have 
been used to probe the general G6PD deficiency status 
in populations [14]. G6PD variants are classified accord-
ing to their residual enzyme activity into three types [15]. 
These range from the most severe presentations but rare 
type 1, that present with congenital nonspherocytic anae-
mia, while type 2 are usually asymptomatic in the steady 
state until exposed to exogenous triggers. These type 2 
variants are the equivalent of class II and III of the WHO 
classification system [8] and predisposes individuals to 
substantial risk of haemolytic anaemia. Type 2 variants 
include the Mediterranean, A−, Mahidol, Canton, Vanua 
Lava and Seattle variants amongst others [16]. Type 3 
variants manifest phenotypically as normal G6PD activ-
ity with no clinical issues.
In sub-Saharan Africa, three variants are most com-
monly described, namely the B wild-type variant associ-
ated typically with normal G6PD activity and the G6PD 
African variants, A+ and A− [16]. The African variants 
(“A”) are amongst the most common in the world with a 
wide enzyme activity range [7]. The A+ variant carries an 
A376G mutation in exon V which results in mild enzyme 
deficiencies. By contrast, the more common A− variant 
which carries an additional mutation in exon IV (G202A) 
is associated mild clinical presentations such as jaundice 
and dark urine when exposed to 8-aminoquinolines [16]. 
Several other A− mutations (A542T, G680T and T968C) 
have been detected in West African individuals [17, 18].
PQ efficacy is further modulated by the human 
cytochrome P450 2D6 (CYP2D6) enzyme [19], which 
metabolizes ~ 25% of all clinically prescribed drugs [20]. 
CYP2D6 is highly polymorphic with varied enzymatic 
activity as a result of allelic sequence variations and pro-
tein structural rearrangements. These genotypic and 
phenotypic variations affect drug metabolism, probably 
increasing the risk of treatment failure or potential tox-
icity [21]. To date, more than 113 allelic variants (and 
sub-variants) of the CYP2D6 gene have been reported 
[22], which can be classified in four distinct pheno-
typic groups. Poor metabolizers (PMs) have two copies 
of defective alleles resulting in reduced expression of a 
particular CYP2D6 enzyme. Intermediate metabolizers 
drug. PQ would pose minimal risks to the study populations and could be a useful elimination strategy in the study 
area.
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Page 3 of 11Awandu et al. Malar J  (2018) 17:120 
(IMs) are heterozygous for a defective allele and a func-
tional allele resulting in slightly reduced enzyme activ-
ity. Extensive metabolizers (EMs) carry two functional 
alleles and have normal enzyme activity, while ultra-rapid 
metabolizers (UMs) have more than two functional gene 
copies and elevated enzyme activity [23]. The PMs with 
the CYP2D6*4 polymorphism are associated with PQ 
treatment failure in P. vivax [24], whereas IMs harbour-
ing CYP2D6*17 mutations have been linked with dimin-
ished enzyme activity in black Africans [25]. Whilst the 
impact of CYP2D6 metabolizer status on the efficacy of 
single low-dose PQ for gametocyte clearance is currently 
unknown, it is conceivable that the gametocytocidal 
effect of PQ would be reduced if lower plasma concentra-
tions of the active PQ metabolite are achieved [26].
Prevalence of G6PD deficiency and CYP2D6 polymor-
phisms in a population are thus important considerations 
for public health interventions involving the deployment 
of 8-aminoquinoline drugs like PQ [27]. In sub-Saharan 
Africa, prevalence of G6PD deficiency is estimated to 
range between 5 and 37.5% [9], and CYP2D6 allele fre-
quencies range from 1 to 33% [28]. South Africa has 
previously (1940s–1980s) reported fewer cases of G6PD 
deficiency (5.3%) [29, 30] and CYP2D6 (2.6%) [31] muta-
tions compared to its neighbouring countries, most likely 
a consequence of genetic differences among the dis-
tinct ethnic groups [32, 33]. However, recent population 
movements and immigration [34] may have led to shifts 
in the frequency of the enzyme deficiency and CYP2D6 
variants across the country. Due to a paucity of current 
data, regionally-relevant evidence of G6PD deficiency 
and CYP2D6 variant metrics are needed. These will 
inform implementation of single low-dose PQ policy in 
pre-elimination settings within South Africa.
This study aimed to determine the current prevalence 
of both G6PD deficiency and CYP2D6 variants in rep-
resentative populations in a malaria-endemic region 
of South Africa. G6PD deficiency measurements were 
also compared to phenotypic screening with a potential 
point-of-care tool in mass screen and test scenarios. This 
is the first study employing genotyping to evaluate locally 
relevant G6PD deficiency and CYP2D6 variants in a pre-
elimination setting of South Africa.
Methods
Ethics statement
Ethical approval for the study was obtained from the 
ethical review committees of the University of Preto-
ria (Ethics reference No. 406/2014) and the Limpopo 
Department of Health (Ref 4/2/2). Signed informed 
consent in the local language (Tshivenda) was obtained 
from all participants prior to sample collection. Parents 
or guardians of children less than 7  years of age gave 
written, informed consent, while children between the 
ages of 7 and 17  years gave assent before sampling. An 
adult witness was required to co-sign the informed con-
sent document.
Study site and population
This study was conducted in the Vhembe District, a 
25,597 km2 area in Limpopo Province, a malaria-endemic 
region in the northernmost part of South Africa. Malaria 
transmission primarily occurs during the months of 
September to May, with limited transmission generally 
occurring over the winter months of June and July [35]. 
Vhembe District is responsible for more than 60% of all 
reported malaria cases in South Africa [36], with 1543 
cases and 18 deaths noted in the region in the 2015/16 
transmission season, when sampling occurred [37, 38]. 
The district is bordered by Mozambique to the south-
east, Zimbabwe to the north and Botswana to north-
west. The climate is typically subtropical with mild 
winters and wet, warm summers with average rainfall per 
annum of 820 mm [39]. The district experiences frequent 
droughts with areas that are predominantly semi-arid 
[40].
Study participants were recruited from six primary 
health care clinics (PHCs): Folovhodwe, Madimbo, 
Manenzhe, Masisi, Mulala and Tshipise in Mutale and 
Musina local municipalities (Fig. 1) during October and 
November 2015. Once recruited into the study in one 
particular clinic, patients were ineligible for subsequent 
enrolment even if they presented at a different clinic. The 
district has an estimated population of 1,347,235 with a 
population density of 52.6 persons per  km2 [41]. The area 
is mainly inhabited by the Venda ethnic group, with siz-
able Zimbabwean immigrant populations (Shona and 
Ndebele ethnic groups) that work on the commercial 
farms and reside in the area.
Questionnaire administration and sample collection
A brief questionnaire on demographics (specifically age 
and gender), travel history, history of fever or any malaria 
symptoms, ethnicity and residence was administered 
to the consenting participants. Upon completion of the 
questionnaire, finger prick filter paper (Munktell TFN 
card, Lasec, Cape Town, South Africa) blood spots were 
collected from the participants for P. falciparum parasite 
detection and human genotyping studies. Sample size in 
this pilot study was constrained by the availability of Car-
eStart™ G6PDd rapid diagnostic test (RDT) kits.
Malaria parasite detection
Peripheral finger prick blood samples were tested for P. 
falciparum parasite antigens using RDT kits detecting 
the histidine-rich protein 2 (First  Response® Malaria 
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Antigen P. falciparum card test HRP2, Premier Medical 
Corporation, India) in accordance with the South African 
National Malaria Diagnosis Quality Assurance guidelines 
[42, 43]. The test was performed on individuals present-
ing with fever at the PHCs. The presence of P. falciparum 
parasites was confirmed by multiplex polymerase chain 
reaction (PCR) as previously described [44].
G6PD phenotypic screening
The CareStart™ G6PD RDT (Access Bio Inc., New Jersey, 
USA) was administered concurrently with the malaria 
RDT on 248 participants at the PHCs as per the manu-
facturers’ guidelines. Briefly, a finger prick blood sample 
(2 µl) was collected through the sample pipette, applied 
into the sample well and 2 drops (~ 100  µl) of assay 
buffer added. The test was developed at room tempera-
ture (25 °C) for 10 min, after which the results were read 
by two blinded primary evaluators, with a third blind 
evaluator acting as a tiebreaker to make the final deci-
sion in case of discrepancies. Normal G6PD individuals 
were classified according to the development of a dis-
tinct purple coloured test band, while in G6PD-deficient 
patients, no purple coloured test band developed. A test 
was declared invalid when either no or incomplete blood 
migration took place.
G6PD genotyping
DNA was extracted from blood-saturated filter paper 
discs of 3  mm diameter using the Chelex method [45]. 
Specific regions of the G6PD gene were amplified and 
subjected to restriction fragment length polymorphisms 
(RFLP, all restriction enzymes sourced from New Eng-
land Biolabs, Inc., USA) to detect mutations as previously 
described [14]. A 308 base pair (bp) amplicon was ampli-
fied from genomic DNA and subjected to FokI digestion 
for 60  min at 37  °C. Uncut fragments were classified as 
G6PD variant B, while samples where two fragments of 
184 and 124 bp were produced, were classified as G6PD 
A+ variants. Only samples positive for G6PD A+ muta-
tions underwent further PCR amplification and RFLP 
Fig. 1 Map of the study site in Vhembe District, Limpopo Province, South Africa. The six primary health care clinics (H) and village catchment areas 
where participants were recruited are indicated. The study district in Limpopo Province is shown alongside other malaria‑endemic provinces of 
KwaZulu‑Natal and Mpumalanga, is in close proximity to Botswana, Zimbabwe and Mozambique
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analysis to detect additional mutations. Subsequent 
digestion was performed with N1aIII (G202A; 211, 81 
and 130  bp), BspEI (G542T; 130, 80 and 50  bp), BstNI 
(G680T; 115, 98 and 29  bp) and NciI (T968C; 282, 162 
and 120 bp) for 60 min at 37 °C (except for BstNI where 
digestion occurred at 60 °C). All G6PD deficiency restric-
tion products were resolved on 3% agarose/TAE gel with 
ethidium bromide staining. Images were captured on 
UVDoc HD2 transilluminator (UVITEC, Cambridge, 
UK).
CYP2D6 genotyping
Genotyping of CYP2D6*4 was performed by PCR ampli-
fication of a 309  bp segment of the CYP2D6 gene fol-
lowed by overnight digestion with BstNI at 60  °C as 
previously described [46], resulting in a 309 bp fragment 
for wt/wt CYP2D6*4; 309, 201 and 108 bp fragments for 
wt/mt CYP2D6*4 or 201 and 108  bp fragments for mt/
mt CYP2D6*4. CYP2D6*17 genotyping was performed 
by PCR amplification of a segment of the cyp2d6 gene of 
interest and subsequent overnight digestion with BtsCI 
as previously described [46], resulting in 407, 328, 79, 
67 and 55  bp fragments for wt/wt. For CYP2D6*17 wt/
mt the resulting fragment sizes were 407, 328, 79, 67 and 
55  bp; mt/mt CYP2D6*17 resulted in 328, 79, 67 and 
55 bp fragments. For all the CYP2D6 variants, the PCR 
and restriction products were resolved on 1.5% agarose/
TAE with ethidium bromide staining gel. Images were 
captured on UVDoc HD2 transilluminator.
Sanger sequencing
All G6PD A− positive PCR products were confirmed 
with Sanger nucleotide sequencing. After purification 
with the  NucleoSpin® Gel and PCR clean-up kit (Mach-
erey–Nagel, Duren, Germany), samples resuspended in 
HiDi™ formamide were sequenced using an ABI PRISM 
 BigDye® terminator V3.1 cycle sequencing kit and pro-
cessed on ABI PRISM 3130xl and ABI PRISM 3500xl 
genetic analyzers (Applied Biosystems™/Life Technolo-
gies, Carlsbad, USA). BLAST queries were conducted for 
preliminary identifications of the sequences and there-
after analysed with MAFFT v 7.182 and CLC sequence 
viewer software.
Data analysis
Data were analysed with SPSS version 20 (IBM Corp. 
NY, USA). Descriptive statistics were used to report the 
demographics of the participants, with phenotype and 
genotype being presented per PHC. Differences in pro-
portions of individuals carrying the G6PD deficiency, 
CYP2D6*4 and CYP2D6*17 wildtype and mutant alleles 
were compared by Chi squared (χ2) tests. Odds ratios 
(ORs) were used to assess any association of G6PD 
deficiency, CYP2D6*4 and CYP2D6*17 occurrence based 
on gender. To test for conformity with the Hardy–Wein-
berg equilibrium (HWE), allele frequencies were ana-
lysed both by PHC and overall. The expected female 
allele frequencies were calculated based on male geno-
type prevalence (A+, A− and B) then compared with 
observed values using Chi squared tests as described 
[14]. The negative predictive value (NPV) of the Car-
eStart™ G6PD deficiency kit was determined using the 
A− variant PCR–RFLP genotyping results as the ‘gold 
standard’ [47]. Agreement between the two test results 
was evaluated using Cohen’s Kappa coefficient (κ), with 
the following scale used to score strength of agreement; 
0.01−0.20 slight; 0.21–0.40 fair; 0.41–0.60 moderate; 
0.61–0.80 substantial and 0.81–1.00 almost perfect [48]. 
A P value of < 0.05 was considered statistically significant.
Results
Study participant characteristics and malaria parasite 
detection
From the six PHCs, a total of 248 participants were 
recruited into the study. More female participants 
(n = 193, 78%) compared to male participants (n = 55, 
22%) were enrolled, with study participants’ median ages 
of 31  years for females (range 1–94) and 21  years for 
males (range 1–81). The majority (97%, 241/248) of par-
ticipants self-identified as South African Venda ethnicity. 
Other ethnic groups screened included Pedi (1.2%, 3/248) 
and Tsonga (0.4%, 1/248), with 1.2% (3/248) Shona from 
Zimbabwe. None of the participants harboured detect-
able P. falciparum parasites by either P. falciparum RDT 
or single-step, multiplex PCR.
G6PD genotyping
The prevalence of the A+ and A− African G6PD variants 
among the study participants was determined by geno-
typing. Of the 248 participants screened, just over half 
(52%, 129/248) carried the G6PD normal B allele (Fig. 2a). 
The A376G mutation in exon V was detected in 32% 
(79/248) of the participants, identifying these individu-
als as carrying the A+ variant. A total of 13% (32/248) of 
the participants were G6PD A− heterozygous individu-
als. Only a minority of participants (3.2%, 8/248), were 
hemizygous or homozygous for the G6PD A− (A376G/
G202A) variant. Among males, G6PD A− hemizygous 
individuals constituted 11% (6/55), while among females, 
1% were G6PD A− homozygous (2/193). All G6PD A− 
variants identified contained A376G/G202A mutations, 
which was independently confirmed by DNA sequenc-
ing. The A542T, G680T or T968C mutations were not 
detected in the study population.
When comparing the proportions of participants 
with G6PD A+ and A− variants in the population, 
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considerable variations were observed among localities 
(P = 0.01 for A+ and P = 0.05 for A− genotypes, respec-
tively). In Manenzhe PHC, the highest proportion (64%) 
of G6PD B variants but lowest proportion (8%) of G6PD 
A− variants were detected. All the A− participants 
from Madimbo and Manenzhe PHC were A− heterozy-
gous females (Fig.  2b). Mulala PHC recorded the high-
est proportions of A− hemizygous participants (11%) 
while homozygous participants (6%) were only identified 
from Tshipise PHC. All of the A− deficient participants 
G6PDd were of Venda ethnicity.
The genotypic frequencies were tested to confirm 
adherence to the HWE. According to the principle, the 
genetic variation in a population should remain constant 
from generation to generation in the absence of disturb-
ing factors. The HWE measurement indicated that in 
general, female gene frequencies did not significantly 
differ from predicted male gene frequencies (χ2 > 0.05). 
However, departures from HWE were seen for the G6PD 
deficiency variants for the general population (χ2 = 0.007) 
and in Tshipise PHC (χ2 = 0.009) (Table  1) where all of 
the study homozygous participants were reported. When 
comparing G6PDd A + and G6PDd A- genotypes, no dis-
tinctive association with gender was observed (P = 0.107 
and 0.441, respectively).
Phenotypic G6PD screening
The CareStart™ G6PD deficiency RDT test kit was used 
for phenotypic evaluation of G6PD status in the test 
population, to explore its utility as point-of-care tool. 
The CareStart™ G6PD deficiency RDT identified 13% 
(33/248) of participants as G6PD-deficient (Table  2), 
with males showing a higher prevalence of G6PD defi-
ciency (18%; 10/55) compared to females at 12% (23/193) 
(odds ratio 1.642; 95% confidence interval 0.7293–3.6992, 
P = 0.229). All the identified G6PD-deficient individuals 
bar one (Tsonga) were of Venda ethnic origin.
The CareStart™ G6PD deficiency RDT was able to 
detect all the genetically-determined G6PD-deficient 
hemizygous males and homozygous females (Table  2) 
with the highest risk of haemolysis. Comparison of 
the RDT phenotyping results with that of the G6PD 
A− (A376G/G202A) PCR–RFLP genotyping indi-
cated specificity of 91.3% (95% CI 86.7–94.8) with 
Fig. 2 G6PD genotype prevalence. a G6PD genotypes (B patterned bar; A+ (A375G) white bar; A− (A375G/G202A) heterozygous light grey 
bar, hemizygous and homozygous dark grey bar) identified with PCR–RFLP and confirmed by sequencing for all the study participants. b G6PD 
deficiency stratified for each of the 6 primary health care clinics in Vhembe District, Limpopo Province, South Africa. (B patterned wedge; A+ 
(A375G) white wedge; A− (A375G/G202A) heterozygous light grey wedge, hemizygous and homozygous dark grey wedge)
Page 7 of 11Awandu et al. Malar J  (2018) 17:120 
a fair Cohen’s Kappa agreement (κ = 0.310). A more 
substantial agreement was observed among the males 
(κ = 0.711) than among the females (κ = 0.202). The 
negative predictive value for identifying hemizygous, 
homozygous and heterozygous participants by RDT 
was 0.88 (95% CI 0.85–0.91) compared to genotyping.
Cytochrome P450 genotype and phenotype distribution
Mutations in the cyp2d6 gene that could interfere with 
PQ activation were evaluated on the 248 collected sam-
ples (Table  3). Allele frequencies of 0.03 and 0.19 were 
detected for the CYP2D6*4 and CYP2D6*17 alleles, 
respectively. Only 2 of the study participants (0.8%, 
2/248) were classified as mt/mt PM with activity scores 
Table 1 Frequency of  G6PD genotypes in  6 primary health care clinics in  Vhembe District, Limpopo Province, South 
Africa
G6PD genotypes: male (X*Y) hemizygous deficient A−, male (XY) normal A+ or B; female (X*X*) homozygous deficient = A−/A−; female (X*X) heterozygous 
deficient = A+/A− or B/A−; and female (XX) normal = A+/A+, B/B or B/A+
NC = not calculated as all males tested in Madimbo clinic carried the G6PD B variant
* P values < 0.05 indicate significant differences from predicted G6PD allele frequencies in females based on male allele frequencies for A−, A+ and B alleles using the 
Hardy–Weinberg equation (χ2)
Genotypes HW P(χ2)
Males Females
No. A− A+ B No. A−A− A+A− BA− A+A+ BB BA+
Folovhodwe 10 1 4 5 43 0 5 3 0 24 11 0.880
Madimbo 6 0 0 6 51 0 1 6 2 24 18 NC
Mananzhe 9 0 3 6 38 0 1 3 2 24 8 0.548
Masisi 11 1 2 8 25 0 1 5 1 11 7 0.197
Mulala 7 2 2 3 11 0 1 0 3 3 4 0.317
Tshipise 12 2 1 9 25 2 1 5 1 6 10 0.009*
Totals 55 6 12 37 193 2 10 22 9 92 58 0.007*
Table 2 G6PD deficiency status amongst  males and  females participants per  primary health care clinic according 
to the CareStart™ G6PD RDT
a No of participants and (%) indicated
b From the deficient females by CareStart™ G6PD RDT test, 2 were homozygous, 7 heterozygous and 14 normal
c From the 170 normal females, 25 were heterozygous and 145 normal
CareStart™ G6PDd RDT 
 classificationa
Males (n, %) Females (n, %)
Deficient (10, 18%) Normal (45, 82%) Deficient (23, 12%)b Normal (170, 88%)c
Primary health care  clinicsa
Folovhodwe 2 (4%) 8 (14%) 7 (4%) 36 (19%)
Madimbo 1 (2%) 5 (9%) 1 (0.5%) 50 (26%)
Manenzhe 1 (2%) 8 (14%) 5 (3%) 33 (17%)
Masisi 2 (4%) 9 (16%) 3 (1%) 22 (11%)
Mulala 2 (4%) 5 (9%) 5 (3%) 6 (3%)
Tshipise 2 (4%) 10 (18%) 2 (1%) 23 (12%)
Table 3 Prevalence of CYP2D6*4 and CYP2D6*17 alleles and inferred phenotypes amongst study participants
The genotypes were determined by PCR–RFLP. Genotypes: wildtype/mutant (wt/mt) and mutant/mutant (mt/mt). All genotyping experiments were performed in 
duplicate in two independent experiments. Inferred phenotypes: intermediate metaboliser (IM) and poor metaboliser (PM)
CYP2D6 alleles Enzyme activity Heterozygote (wt/
mt)
Homozygote (mt/
mt)
Allele frequency Activity score Inferred 
phenotype
CYP2D6*4 Non‑functional 12 2 0.0323 0 PM
CYP2D6*17 Reduced 67 15 0.1956 0.5–1 IM
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(AS) of 0 with a minor proportion (6%, 15/248) classi-
fied as mt/mt IM (AS of 0.5–1.0), using the AS metric as 
described [49]. The majority of the population (231/248, 
93%) was classified as extensive or normal metabolizers. 
No association between gender and either the CYP2D*4 
(χ2, P = 0.731) or CYP2D6*17 (χ2, P = 0.906) genotype 
was noted.
Discussion
This study reports on the prevalence of G6PD deficiency 
as well as CYP2D6*4 and CYP2D7*17 mutations in a 
southern African malaria pre-elimination setting, with 
the aim of informing a low-dose PQ policy. The G6PD 
A− prevalence of 11% among hemizygous males was 
comparable to that previously reported in South Afri-
can Venda ethnic group [50]. Higher G6PD deficiency 
prevalence among males was previously reported in 
ethnic groups residing in close proximity to neighbour-
ing Mozambique and Zimbabwe [30, 50], consistent 
with the observations in this study. These countries have 
higher malaria transmission intensity compared to South 
Africa, which could explain their higher G6PD deficiency 
prevalence of up to 19% in males [51, 52]. Modelling 
the median population estimates for G6PD allele fre-
quency predict low frequencies of 3.3% for South Africa 
[15]. However, maps aggregate average frequency data 
to national levels and may mask sub-national variation 
and local heterogeneity in G6PD deficiency. By contrast, 
in Swaziland, a study on PQ pharmacovigilance in two 
health facilities reported the absence of G6PD deficiency 
amongst 102 participants [53].
The presence of A− (A376G/G202A) variant was con-
firmed in G6PD-deficient individuals, corroborating 
its previously-described widespread distribution [29, 
50]. Other G6PD variants such as the A542T, G680T or 
T968C mutations previously reported in the Gambia and 
Senegal [17, 18], were not identified in the current south-
ern African study population. This is consistent with 
findings from two large randomized controlled multicen-
tre studies in Africa [14, 54]. While the study aimed to 
inclusively genotype different G6PD deficiency variants 
identified as important in African settings, the presence 
of additional G6PD deficiency variants in the locality 
cannot be ruled out. Future studies using more novel and 
robust genotyping methods are envisaged, as they could 
identify novel mutations that may impact PQ roll-out 
[32].
PQ is an important addition to standard malaria treat-
ment regimen to aid in transmission reduction, especially 
for countries on the cusp of elimination [6]. PQ efficacy 
may be influenced by individual and ethnic genetic differ-
ences amongst populations [21, 55] and is reliant on met-
abolic activation. The PM and IM CYP2D6 phenotypes 
observed (3.2 and 19.5%, respectively) may result in 
PQ treatment failure at the recommended 0.25  mg/kg 
dose [56]. These findings on CYP2D6*4 allele frequency 
and predicted PM phenotype is consistent with earlier 
reported 1.3% [31] and 4% [57] prevalence among the 
Venda ethnic group. Indigenous African blacks have 
consistently been reported with a high frequency of the 
CYP2D6*17 allele, in agreement with reported data in 
this study [31, 33, 58].
As South Africa moves towards malaria elimination, 
novel interventions such as the WHO-recommended 
low-dose PQ strategy need further exploration. How-
ever, individuals with the CYP2D6*4 variants that may 
be unresponsive to PQ treatment and CYP2D*17 vari-
ants, who may require higher PQ dose to ensure thera-
peutic efficacy, is cause for concern in the country [56]. 
While there is little conclusive evidence on the effect of 
PQ on community–wide transmission if deployed in 
mass drug administration [59], efficacy studies point to 
marked reduction in duration of gametocyte carriage [4, 
60]. The PQ-associated gametocyte clearance and its out-
comes on mosquito infectiousness depends on malaria 
transmission settings and the choice of artemisinin com-
bination therapy. It has been demonstrated that PQ has 
modest benefits on asymptomatic individuals with lower 
parasite densities prior to initiation of combination PQ 
treatment with either artemether-lumefantrine [26] or 
dihydoartemisinin-piperaquine [60]. That PQ should not 
be administered to infants aged < 6 months, breastfeed-
ing women of infants aged < 6 months as well as pregnant 
women (South Africa has a 12% teenage pregnancy rate 
and higher fertility rates among non-urban women) [61], 
identifies the treatment gaps for PQ, with impact depend-
ent on the proportion of the population treated [62].
Accumulating evidence from Africa [63–65] and Asia 
[66], suggests that single-dose PQ at 0.25  mg/kg as a 
gametocytocidal drug to block transmission would be 
safe in areas where G6PD deficiency A− and other type 
2 variants predominates, comparable to the settings in 
this study site. Encouraging evidence from neighbour-
ing Swaziland, a country with a similar G6PD deficiency 
prevalence profile to South Africa, suggests the roll-out 
of a low-dose PQ policy with no prior genetic profiling 
requirement, at least in none G6PD-deficient partici-
pants by RDT, is associated with good safety profiles [53]. 
However, stringent pharmacovigilance and patient moni-
toring systems should be put in place to mitigate any 
adverse events. Further, the low levels of CYP2D6 PM 
and IM is encouraging for the use of single low-dose PQ 
as an adjunct to current malaria control tools, and may 
accelerate efforts to eliminate malaria in South Africa.
This study was limited by the small sample size con-
strained by the availability of the G6PD RDT tests. 
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Moreover, a potential selection bias towards females 
(78%) was present in the sample set, and findings may, 
therefore, not be directly extrapolated to estimate the 
overall population structure and deficiency prevalence 
in the study area, which can be rectified through more 
general population sampling, rather than sampling only 
at PHC facilities. Since the study only deployed a G6PD 
deficiency RDT, enzymatic activity validation is ulti-
mately required to evaluated functional loss of G6PD 
activity to disentangle female heterozygotes from defi-
cient and the non-deficient females. Female gender 
segregation would control for the profound effects of 
comparing male hemizygous and female heterozygous on 
diagnostic performance of G6PD tests [67].
Conclusions
Phenotypic and genotypic analysis both detected a 
low prevalence of individuals carrying the G6PD A−, 
CYP2D6*4 PM variants and modest prevalence of the 
CYP2D6*17 IM variants in the study area. These pre-
liminary findings suggest the deployment of single low-
dose PQ poses a minimal risk to the area populations 
and could be useful in elimination strategies, in localized 
areas of South Africa.
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